Allergic Bronchopulmonary Aspergillosis (ABPA) was first described by Hinson and colleagues in 1952. ABPA is a hypersensitivity disorder induced by a fungus Aspergillus and affects non-immunocompromised patients. The diagnosis is based on the presence of a combination of clinical, biological and radiological criteria. The treatment is based on oral corticosteroids for 6-8 weeks at acute phase o...

Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disease with small prevalence. Exposure to aspergillus mold causes immunologic hypersensitivity and may cause ranges of symptoms from minimal to detrimental outcomes. Diagnosing and treating the disease before the development of bronchiectasis may save the patient from poor outcomes. This report presents a case of recurrent ABPA with...

BACKGROUND There is increasing evidence for the efficacy of the antifungal voriconazole, particularly in immunosuppression. We describe our experience of using voriconazole in children with CF. METHODS We performed a retrospective case note review of children with CF treated with voriconazole in a single centre over an 18 month period. RESULTS A total of 21 children aged 5 to 16 years (medi...

PURPOSE OF REVIEW Despite guideline-based treatment, many patients with severe asthma continue to have uncontrolled disease. Fungal allergy is being increasingly recognized in the pathogenesis of severe asthma. Limited data exist on the approach to treatment of fungal asthma. This review summarizes existing evidence on the use of antifungal agents in allergic bronchopulmonary aspergillosis (ABP...

BACKGROUND Allergic bronchopulmonary aspergillosis (ABPA) is a common serious hypersensitivity reaction to airway colonization with Aspergillus in patients with asthma or cystic fibrosis. While steroids are effective in controlling the respiratory symptoms of ABPA, they have many side effects that make them undesirable for long term use. Antifungals have been used to reduce dependency on system...

1 of 2 DESCRIPTION A 30-year-old female referred to our department as case of suspected multi-drug resistant tuberculosis with drug induced liver injury. She was on irregular antitubercular treatment (ATT) for past 2.5 years without improvement as prescribed by different physicians. Sputum examination for acid fast bacilli (AFB) was never done. Physical examination revealed bilateral polyphonic...

Allergic bronchopulmonary aspergillosis (ABPA) is a devastating clinical disease that results from an aggressive pulmonary allergic response to the antigens released by colonizing Aspergillus fumigatus (A. fumigatus) in the respiratory system. Many of the allergic features of clinical ABPA have been reproduced in murine models, thereby facilitating a detailed analysis of the inflammatory and im...

BACKGROUND AND OBJECTIVES It would be of considerable interest to clinicians if the burden of chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA) in India were known. Herein, we estimate the burden of CPA following pulmonary tuberculosis (PTB), and ABPA (and severe asthma with fungal sensitization [SAFS]) complicating asthma. METHODS We used the population...

Streptococcus pneumoniae is a major human pathogen associated with many diseases worldwide. Capsular polysaccharides (CPSs) are the major virulence factor. The biosynthetic pathway of D-arabinitol, which is present in the CPSs of several S. pneumoniae serotypes, has never been identified. In this study, the genes abpA (previously known as abp1) and abpB (previously known as abp2), which have pr...

BACKGROUND AND OBJECTIVE Very little is known about the response rates to or appropriateness of treatment for patients with allergic fungal diseases of the lung. This study assessed the effect of antifungal therapy in patients with severe asthma with fungal sensitization (SAFS) and allergic bronchopulmonary aspergillosis (ABPA). METHODS A retrospective cohort study of 33 adult patients who fu...